Document Detail


Hexylaminolaevulinate fluorescence cystoscopy in patients previously treated with intravesical bacille Calmette-Gu?rin.
MedLine Citation:
PMID:  19832725     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE To determine if hexylaminolaevulinate fluorescence cystoscopy (HAL-FC) has the potential to improve the diagnosis of bladder cancer in patients who have been treated with bacille Calmette-Gu?rin (BCG). PATIENTS AND METHODS Patients scheduled for rigid cystoscopy after BCG therapy were recruited prospectively between April 2005 and February 2006. Patients received HAL (Hexvix, PhotoCure ASA, Oslo, Norway) and the D-light system (Storz, Tuttlingen, Germany) was used to detect fluorescence. The bladder was mapped and biopsies taken under white light and then using HAL-FC. The main outcome was the frequency and nature of additional pathology detected by HAL-FC. Twenty-seven patients (21 men and six women; median age 70 years, range 49-82) underwent 32 HAL-FC. RESULTS Recurrent bladder cancer was detected in 11 of the 32 (34%) examinations. HAL-FC detected additional pathology in five of the 27 (19%) patients. In two of these cases the additional pathology was clinically significant (one pT4G3 intraprostatic transitional cell carcinoma and one intravesical pT1G2 + carcinoma in situ), whereas in three cases the pathology was hyperplasia/dysplasia. Overall, the false-positive biopsy rate with HAL-FC was 63%. In the presence of positive voided urine cytology six of eight patients had recurrent bladder tumour and the false-positive biopsy rate was only 34%. Urine cytology was positive in four of five of the patients in whom additional pathology was detected by HAL-FC. CONCLUSIONS Clinically significant occult pathology can be detected using HAL-FC after BCG therapy, but in <10% of cases. The rate of false-positive biopsies is high but in our hands appears to be lower than with white-light guided biopsies after BCG. Our pragmatic approach is to use HAL-FC after BCG when clinical suspicion is high, and when the preoperative voided urine cytology is positive.
Authors:
Eleanor R Ray; Kathryn Chatterton; M Shamim Khan; Ashish Chandra; Kay Thomas; Prokar Dasgupta; Tim S O'Brien
Related Documents :
21600505 - Changes in language pathways in patients with temporal lobe epilepsy: diffusion tensor ...
3506095 - Fine-needle aspiration of the spleen as an aid in the diagnosis of splenomegaly.
22821995 - The severity of shock is associated with impaired rates of net alveolar fluid clearance...
22069235 - Perfusion parameters analysis of the vertebral bone marrow in patients with ph(1-) chro...
21508885 - Ultrasonographic evaluation of risser's sign; is it a reliable and reproducible method?
25395095 - Salivary biomarkers indicate obstructive sleep apnea patients with cardiovascular disea...
Publication Detail:
Type:  Evaluation Studies; Journal Article     Date:  2009-10-13
Journal Detail:
Title:  BJU international     Volume:  105     ISSN:  1464-410X     ISO Abbreviation:  BJU Int.     Publication Date:  2010 Mar 
Date Detail:
Created Date:  2010-03-31     Completed Date:  2010-04-27     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  100886721     Medline TA:  BJU Int     Country:  England    
Other Details:
Languages:  eng     Pagination:  789-94     Citation Subset:  IM    
Affiliation:
Department of Histopathology, Guy's and St. Thomas' NHS Foundation Trust, London, UK.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Administration, Intravesical
Aged
Aged, 80 and over
Aminolevulinic Acid / analogs & derivatives*,  diagnostic use
Antineoplastic Agents / therapeutic use
BCG Vaccine / therapeutic use
Cystoscopy / methods*,  standards
Epidemiologic Methods
Female
Humans
Male
Middle Aged
Neoplasm Recurrence, Local / diagnosis*
Photosensitizing Agents / diagnostic use*
Urinary Bladder Neoplasms / diagnosis*,  drug therapy
Chemical
Reg. No./Substance:
0/5-aminolevulinic acid hexyl ester; 0/Antineoplastic Agents; 0/BCG Vaccine; 0/Photosensitizing Agents; 106-60-5/Aminolevulinic Acid

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  15 years of continent urinary diversion and enterocystoplasty in children and adolescents: the W??rz...
Next Document:  Review article: Anti-fibrotic agents for the treatment of Crohn's disease - lessons learned from oth...